InvaGen Pharmaceuticals - Ownership and Business Overview

Life ScienceCompany

InvaGen Pharmaceuticals Ownership

Who owns InvaGen Pharmaceuticals?

InvaGen Pharmaceuticals is owned by Cipla. It was acquired on September 3, 2015.

InvaGen Pharmaceuticals Business Overview

Where is InvaGen Pharmaceuticals headquartered?

InvaGen Pharmaceuticals is headquartered in Hauppauge, New York.

What sector is InvaGen Pharmaceuticals in?

InvaGen Pharmaceuticals is a life science company.

When was InvaGen Pharmaceuticals founded?

InvaGen Pharmaceuticals was founded in 2003.

Life Science M&A Summary in 2015

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2015. The largest life science acquisition in 2015 was Allergan - which was acquired by Allergan for $70.5B.

Join Mergr to view all 293 acquisitions of life science companies in 2015, including 32 acquisitions by private equity firms, and 261 by strategics.

InvaGen Pharmaceuticals, Inc.

7 Oser Avenue,
Hauppauge, New York 11788
United States,
(631) 231-3233
www.invagen.com

InvaGen Pharmaceuticals, Inc. is a generic pharmaceutical company in the US. InvaGen is engaged in development, manufacturing, marketing and distributing of generic pharmaceuticals with focus on wide range of therapeutic areas including, cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants.


 Subscribe to unlock this and 209,235
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 202K M&A Transactions
  • 205K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.